Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $93.95 which represents a slight increase of $0.55 or 0.59% from the prior close of $93.4. The stock opened at $93 and touched ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small ...

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...